Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.73 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.68 |
| ▸ | HSD17B2 | P37059 | 8/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | ESRRG | P62508 | 4/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639170 | 0.85 | HPGDS (1.00) | HPGDSHSD17B1HSD17B2ESRRGESR1 | |
| SCHEMBL2690201 | 0.84 | IKBKB (0.68) | HPGDSEPHX2IKBKB | |
| SCHEMBL6612574 | 0.83 | HPGDS (0.60) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL3973766 | 0.83 | HSD17B1 (0.53) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL29922717 | 0.82 | EPHX2 (0.58) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL27565420 | 0.82 | ESRRG (0.59) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL28541614 | 0.82 | EPHX2 (0.58) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL27565581 | 0.82 | IKBKB (0.71) | HPGDSHSD17B1HSD17B2EPHX2IKBKB | |
| SCHEMBL24263 | 0.81 | HSD17B1 (1.00) | HSD17B1HSD17B2 | |
| SCHEMBL1181010 | 0.80 | HSD17B1 (1.00) | HPGDSHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | claimed |
| CN-102516115-B | As the antagonist of Opioid Receptors or the new compound of inverse agonist | SMITHKLINE BEECHAN CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103980151-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2014-08-13 | — | — | CN | disclosed |
| CN-101522614-B | Compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP | 2014-06-25 | — | — | CN | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| CN-102516115-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2012-06-27 | — | — | CN | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| CN-101616667-A | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2009-12-30 | — | — | CN | disclosed |
| CN-101522614-A | Novel compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | CN | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-100345847-C | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HPGDS 1061/4885HSD17B1 2970/4885HSD17B2 2553/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | HPGDS 2108/4885HSD17B1 1414/4885HSD17B2 895/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | HPGDS 1061/4885HSD17B1 2970/4885HSD17B2 2553/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | HPGDS 1061/4885HSD17B1 2970/4885HSD17B2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.